Accredited Investors’s Novo Nordisk NVO Stock Holding History

Accredited Investors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,486	Closed	-$212K	–	244
2024 Q2	$212K	Buy	+1,486	New	+$197K	0.01%	206

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Accredited Investors's NVO Position: Q3 2024 in Review

Accredited Investors sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 1,486 shares — an estimated $212K sold.

Accredited Investors first reported a position in NVO in Q2 2024 and held it in 1 quarter. The position peaked at $212K in Q2 2024. 1,785 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

Accredited Investors reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
Accredited Investors sold 1,486 Novo Nordisk shares in Q3 2024, an estimated $212K.
Accredited Investors first reported a position in Novo Nordisk in Q2 2024 and held it in 1 quarter.
Accredited Investors's Novo Nordisk position peaked at $212K in Q2 2024.
1,785 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Accredited Investors's 13F filing for Q3 2024, filed 5 Nov 2024.